MAP2K7 and cancer: The level of phosphorylated ERK is usually monitored to reflect the efficacy of RAF or MEK inhibitors on cancer therapy targeting RAS-ERK signaling, and near-complete and long-lasting inhibition of ERK signaling is a reliable guarantee of durable responses (Samatar and Poulikakos, 2014).